文献速递泌尿男性生殖肿瘤

膀胱内nadofaragene firadenovec基因治疗用于BCG无应答非肌层浸润性膀胱癌:单臂、开放标签、重复给药临床试验

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
PubMed 文献 · Lancet Oncol · 2020-11-27

这项3期单臂开放标签重复给药研究在美国33个中心纳入157例BCG无应答非肌层浸润性膀胱癌患者,膀胱内给予nadofaragene firadenovec 75 mL(3×10^11病毒颗粒/mL),3、6、9个月无高级别复发时重复给药。最常见3-4级药物相关不良事件为排尿紧迫(157例中2例,1%,均为3级),无治疗相关死亡。

要点

  • 给药方案为单次膀胱内75 mL(3×10^11病毒颗粒/mL),3、6、9个月无高级别复发时重复给药。
  • 最常见3-4级药物相关不良事件为排尿紧迫(1%,2/157),无治疗相关死亡。

核心结论

  • 膀胱内nadofaragene firadenovec对BCG无应答非肌层浸润性膀胱癌有效且获益风险比良好。

研究设计与样本

  • 3期、多中心、开放标签、重复给药研究,在美国33个中心(医院和诊所)进行。
  • 纳入≥18岁、BCG无应答非肌层浸润性膀胱癌且ECOG状态≤2的患者,排除上尿路病变、前列腺尿道尿路上皮癌、淋巴血管侵犯、微乳头病变或肾积水者。
  • 198例评估资格,41例排除,157例入组并至少接受一剂研究药物;6例不符合BCG无应答定义被排除,151例纳入符合方案疗效分析。
  • 主要终点为原位癌(伴或不伴高级别Ta或T1肿瘤)患者任意时间的完全缓解,无效假设为该队列完全缓解率低于27%。

主要发现

  • 排尿紧迫是最常见的3-4级研究药物相关不良事件(157例中2例,1%,均为3级),无治疗相关死亡。

关键数值与推荐

  • 无效假设完全缓解率<27%。
  • 给药剂量为单次膀胱内75 mL(3×10^11病毒颗粒/mL),3、6、9个月无高级别复发时重复给药。

临床怎么用

  • 对于BCG无应答的非肌层浸润性膀胱癌,尤其是原位癌伴或不伴高级别Ta或T1肿瘤患者,可考虑膀胱内nadofaragene firadenovec治疗。
  • 治疗期间需监测高级别复发,无高级别复发时按3、6、9个月计划重复给药。
  • 需关注排尿紧迫等不良事件,本研究中3-4级排尿紧迫发生率为1%。

局限性

  • 单臂、开放标签设计,无对照臂。
  • 疗效分析基于符合方案人群(151例),排除了6例不符合BCG无应答定义者。
  • 研究正在进行中,计划4年治疗和监测阶段,长期数据尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer. METHODS: In this phase 3, multicentre, open-label, repeat-dose study done in 33 centres (hospitals and clinics) in the USA, we recruited patients aged 18 years or older, with BCG-unresponsive non-muscle-invasive bladder cancer and an Eastern Cooperative Oncology Group status of 2 or less. Patients were excluded if they had upper urinary tract disease, urothelial carcinoma within the prostatic urethra, lymphovascular invasion, micropapillary disease, or hydronephrosis. Eligible patients received a single intravesical 75 mL dose of nadofaragene firadenovec (3 × 1011 viral particles per mL). Repeat dosing at months 3, 6, and 9 was done in the absence of high-grade recurrence. The primary endpoint was complete response at any time in patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour). The null hypothesis specified a complete response rate of less than 27% in this cohort. Efficacy analyses were done on the per-protocol population, to include only patients strictly meeting the BCG-unresponsive definition. Safety analyses were done in all patients who received at least one dose of treatment. The study is ongoing, with a planned 4-year treatment and monitoring phase. This study is registered with ClinicalTrials.gov, NCT02773849. FINDINGS: Between Sept 19, 2016, and May 24, 2019, 198 patients were assessed for eligibility. 41 patients were excluded, and 157 were enrolled and received at least one dose of the study drug. Six patients did not meet the definition of BCG-unresponsive non-muscle-invasive bladder cancer and were therefore excluded from efficacy analyses; the remaining 151 patients were included in the per-protocol efficacy analyses. 55 (53·4%) of 103 patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour) had a complete response within 3 months of the first dose and this response was maintained in 25 (45·5%) of 55 patients at 12 months. Micturition urgency was the most common grade 3-4 study drug-related adverse event (two [1%] of 157 patients, both grade 3), and there were no treatment-related deaths. INTERPRETATION: Intravesical nadofaragene firadenovec was efficacious, with a favourable benefit:risk ratio, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. This represents a novel treatment option in a therapeutically challenging disease state. FUNDING: FKD Therapies Oy.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2020. PMID: 33253641. doi:10.1016/S1470-2045(20)30540-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。